Bachem in the news

BACHEM's stock increased by 1.1% to 70.10 CHF, with 45,803 shares traded, and analysts project a dividend of 1.01 CHF for 2026.

Insiders, led by Peter Grogg with 58%, hold a majority stake in Bachem Holding AG, reflecting strong insider control and interest in the company's growth.

BACHEM's stock gained 1.4% to 70.50 CHF, approaching its 52-week high, with analysts expecting higher dividends and earnings in 2025.

BACHEM's stock showed a 1.4% gain reaching 70.50 CHF, with strong dividend and earnings forecasts for 2025.

BACHEM's stock gained 1.4% to 70.50 CHF, nearing its 52-week high, with rising dividends and positive earnings forecasts for 2025.

Bachem is growing strongly, driven by weight loss drugs, under new leadership and linked to major construction projects.

Bachem Holding increased its full-year EBITDA by over 20%, focusing on peptide and organic molecule manufacturing for pharma and biotech sectors.

Bachem's stock surged after Royal Bank of Canada raised its price target, citing strong growth prospects from capacity expansion and optimistic earnings forecasts.

Bachem's stock is down but analysts from Basler Kantonalbank and UBS see significant upside potential amid a planned CEO change and strong growth prospects.

The Bachem stock price decreased by 1.5% in morning trading, currently trading at CHF 65.65, with analysts expecting CHF 2.38 in earnings per share for 2026.

Bachem Holding AG increased its 2025 revenue and net profit, achieving higher earnings per share compared to the previous year.

BACHEM's stock fell 10.1% midday, trading at 58.50 CHF, with upcoming Q4 2025 results expected in March 2026 and a dividend forecast of 0.920 CHF.

Bachem is a peptide and oligonucleotide CDMO investing heavily in growth amid margin pressure and volatile stock performance, appealing to risk-tolerant investors focused on biotech expansion.

BACHEM's stock fell 1.9% midday, trading below its 52-week high, with upcoming earnings and dividend forecasts indicating steady performance.

BACHEM's stock declined 0.9% to 69.35 CHF amid trading, with upcoming Q4 2025 results due in March and expected EPS of 1.59 CHF for 2025.

Bachem is a Swiss biotech specialist in peptide and oligonucleotide manufacturing, attracting social media hype due to its contract manufacturing model and growth potential, but its stock is volatile and high-risk.

BACHEM's stock showed a 0.9% gain in morning trading, with dividends expected to rise and Q4 2025 results due in March 2026.

Bachem expects strong revenue growth in 2025 driven by new production capacity despite missing its 1 billion CHF target due to currency effects, while advancing plans for a new site and maintaining high investments.

Bachem opened a new plant in Bubendorf, investing 332.6 million Swiss Francs in 2025 to expand production capacities.

BACHEM stock experienced a 0.4 percent decline to 67.35 CHF, trading below its 52-week high, with upcoming Q2 2026 results anticipated.